Renal cell carcinoma
Conditions
Interventions
Patients are applied Amitose-bis-glyceryl ascorbate to palmar and planter region three times or higher a day with concomitant administration of 10% urea or heparinoid-containing cream.
Sponsors
Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who give informed consent and who are 20 years of age at least 2) Patients who were diagnosed renal cell carcinoma 3) Patients who recieve sunitinib treatment including previously treatment of targeted therapy and neoadjuvant therapy 4) ECOG PS: 0-2 5) Patients who are expected to survive at least 12 weeks 6) Patients who observe the protocol compliance
Exclusion criteria
Exclusion criteria: 1) Patients in whom the underlying disease is a dermatological disease at palmar and planter region at initiation of sunitinib treatment 2) Patients who are applied external medicine not involving 10% urea and heparinoid-containing cream to palmar and planter region at initiation of sunitinib treatment 3) Patients who are not able to apply 10% urea or heparinoid-containing cream to palmar and planter region 4) Patients with HFSR of grade 1 or higher at initiation of sunitinib treatment 5) Patients with infections which needs systemic treatment 6) Patients with severe hepatic disorder 7) Patients with severe renal disorder 8) Patients who are lack of felicity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I: Cutaneous abnormality including erythem, edema, papula, and vesicle Phase II: Incidence of HFSR of grade 1 of higher within 6 weeks after initiation of sunitinib treatment | — |
Countries
Japan
Contacts
Public ContactKauhiro Yamamoto
Kobe University Hospital Pharmacy
Outcome results
None listed